Needham set a target price of 83 dollars for the stock. This is significantly higher than the 41 dollars it currently trades for and sits well above the average analyst target of 62 dollars.
Setting a target price is an analyst's way of saying where they think the stock will be in a year. While targets are just educated guesses, this one suggests a high level of confidence that the company can grow its share of the eye-injection market despite new competition.
The company has a habit of beating expectations, including a surprise profit last quarter. It shows management is doing a good job of controlling costs even while they spend heavily to launch new drugs.
Earnings history
EstimateBeatMiss
Apellis Pharmaceuticals past earnings results
Expected
Actual
Surprise
EPS
$-0.38
$0.15
+139.5%
Revenue
$210M
$268M
+27.5%
Metrics we are tracking
Metric
Expectations
Status
Eye Market Share
Staying above 55% of the geographic atrophy market
60% as of Q4 2025
Kidney Patient Starts
Reaching 600 cumulative start forms by the end of 2026
267 cumulative forms as of Q4 2025
FCF Margin
Reaching a sustained positive free cash flow margin
Positive in 2025 prelims
Syfovre Revenue Growth
Returning to at least 5% annual growth by 2027
-4% YoY in FY2025
Stay on top of Apellis Pharmaceuticals
Follow Apellis Pharmaceuticals to get the latest and most important updates.